Post Early Success, Bristol-Myers Ends Tests for Kidney Cancer

Post Early Success, Bristol-Myers Ends Tests for Kidney Cancer

Bristol-Myers Squibb Co, widely known BMS- a renowned pharmaceutical company in the United States declared on September 6, 2017, that they have succeeded in testing the combination therapy and treatment to boost overall survival in patients suffering from kidney cancer. This success has helped the company to end its trial before the planned schedule, despite previous reports generated had mixed results considering other chief goals.

The company mentioned in a statement that an amalgamation of Yervoy and Opdivo, its two key medications, showed higher total survival rates compared to a standard care medication that was used to treat formerly untreated patients suffering from metastatic or advanced renal cell carcinoma. In August 2017, Bristol- Myers quoted that the amalgamated treatment failed in improving progression-free cancer survival in most of the patients. However, it was successful in decreasing the size of the cancer tumor in many patients.

Research analyst from Leerink, Seamus Fernandez had written in a client note that, “we are of a belief that the total survival advantage is most likely to confirm the durability of the indication noticed on progression-free survival, thus resulting in an extremely high likelihood of medication approval.” As per the information given by Cowen and Co, the trials to gauge the complete survival rates are expected to be executed during the second half of 2019. Bristol-Myers added that the trail was ended before time after the results of a planned interim analysis were successful. This also helped the company shares to went up by 4.2 percent and reach a 52-week high amounting to US$ 62.415 this time.
The shares of Exelixis Inc- a rival pharmaceutical company which is in process of manufacturing a competitive treatment for kidney cancer, dropped down by 10 percent. In addition, trial results of Bristol-Myers increased hopes and expectations for lung cancer therapy from AstraZeneca Plc that failed to deliver progression-free survival in July.

You may be interested

Plastisols Market Applications, Types and Market Analysis to 2026
Chemicals and Polymer Science
Chemicals and Polymer Science

Plastisols Market Applications, Types and Market Analysis to 2026

Alex Mathew - August 14, 2018

Plastisols Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation,…

Business

Phytonutrients Market Revenue Growth Predicted by 2025

Mohit Joshi - August 14, 2018

Phytonutrients Market report provides the statistical analysis of “Phytonutrients Market: Global Industry Analysis, Size, Share, Growth, Trends, Outlook and Forecasts” present in the industry space. The report helps…

Chemicals and Polymer Science

Citric Acid Market Headed for Growth and Global Expansion by 2026

Mohit Joshi - August 14, 2018

Citric Acid Market report provides the statistical analysis of “Citric Acid Market: Global Industry Analysis, Size, Share, Growth, Trends, Outlook and Forecasts” present in the industry space. The…

Most from this category